Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMB38KH)

Drug Name

Elisidepsin Drug Info

Synonyms

Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 2	[1]

Cross-matching ID

PubChem CID: 9855343
ChEBI ID: CHEMBL83152
TTD Drug ID: DMB38KH

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb3 tyrosine kinase receptor (Erbb-3)	TTDC8N2	ERBB3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Erbb3 tyrosine kinase receptor (Erbb-3)	DTT	ERBB3	6.305	7.803	6.897	7.643

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Psoriasis vulgaris

ICD Disease Classification

EA90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Erbb3 tyrosine kinase receptor (Erbb-3)	DTT	ERBB3	7.21E-05	-0.32	-0.62

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug;33(4):901-10.
2	Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.